drugset
drugset / Trial / NCT02469415

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

NCT02469415 ↗

Phase 2 Terminated 3 enrolled M.D. Anderson Cancer Center CTI BioPharma · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if pacritinib, either alone or in combination with azacitidine or decitabine, can help to control MDS. The safety of this drug and drug combination will also be studied.

Timeline

Start
2015-09-30
Primary completion
2017-06-03
Completion
2017-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Intravenous
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Subject Pacritinib Small molecule 200 mg Oral

Indications

leukemia